ATE207119T1 - Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind - Google Patents

Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind

Info

Publication number
ATE207119T1
ATE207119T1 AT93900518T AT93900518T ATE207119T1 AT E207119 T1 ATE207119 T1 AT E207119T1 AT 93900518 T AT93900518 T AT 93900518T AT 93900518 T AT93900518 T AT 93900518T AT E207119 T1 ATE207119 T1 AT E207119T1
Authority
AT
Austria
Prior art keywords
hepatitis
monoclonal antibodies
production
human monoclonal
surface antigen
Prior art date
Application number
AT93900518T
Other languages
English (en)
Inventor
Lars G Ostberg
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Priority claimed from PCT/US1992/009749 external-priority patent/WO1994011495A1/en
Application granted granted Critical
Publication of ATE207119T1 publication Critical patent/ATE207119T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT93900518T 1992-11-06 1992-11-06 Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind ATE207119T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1992/009749 WO1994011495A1 (en) 1992-11-06 1992-11-06 Production of human monoclonal antibodies active against hepatitis b surface antigen

Publications (1)

Publication Number Publication Date
ATE207119T1 true ATE207119T1 (de) 2001-11-15

Family

ID=22231529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93900518T ATE207119T1 (de) 1992-11-06 1992-11-06 Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind

Country Status (5)

Country Link
JP (1) JP2002502222A (de)
KR (1) KR100281163B1 (de)
AT (1) ATE207119T1 (de)
DE (1) DE69232140D1 (de)
RU (1) RU2146706C1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42137A (fr) * 2015-05-22 2021-04-07 Huahui Health Ltd Anticorps vhb anti-pre-s1
CN116196411A (zh) 2016-06-17 2023-06-02 豪夫迈·罗氏有限公司 用于治疗乙型肝炎感染的papd5和papd7抑制剂
KR102431353B1 (ko) 2017-10-16 2022-08-10 에프. 호프만-라 로슈 아게 B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
CN119899273B (zh) * 2025-01-15 2025-10-31 中国人民解放军空军军医大学 一种人pgk1第131位赖氨酸乳酸化修饰的抗体制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61104796A (ja) * 1984-10-26 1986-05-23 Chemo Sero Therapeut Res Inst モノクロ−ナル抗体の製造方法
RU2097425C1 (ru) * 1994-10-12 1997-11-27 Аммосов Алексей Дмитриевич Штамм гибридных культивируемых клеток животного mus musculus l. - продуцент моноклональных антител к a-детерминанте поверхностного антигена вируса гепатита b
RU2092553C1 (ru) * 1994-10-12 1997-10-10 Аммосов Алексей Дмитриевич Штамм гибридных культивируемых клеток животного mus musculus l - продуцент моноклональных антител к а-детерминанте поверхностного антигена вируса гепатита b
RU2097426C1 (ru) * 1994-10-13 1997-11-27 Аммосов Алексей Дмитриевич Штамм гибридных культивируемых клеток животного mus musculus l. - продуцент моноклональных антител к a-детерминанте поверхностного антигена вируса гепатита b

Also Published As

Publication number Publication date
RU2146706C1 (ru) 2000-03-20
KR950704478A (ko) 1995-11-20
JP2002502222A (ja) 2002-01-22
RU95117092A (ru) 1997-03-27
KR100281163B1 (ko) 2001-04-02
DE69232140D1 (de) 2001-11-22

Similar Documents

Publication Publication Date Title
CA2033640A1 (en) Vaccines against cancer and infectious diseases
ATE70309T1 (de) Menschliche monoklonale antikoerper gegen bakterielle toxine.
DE69129743D1 (de) Humanisierte chimäre anti-"icam-1" antikörper, herstellungsverfahren und verwendung
AU2308595A (en) Monoclonal antibodies against hiv-1 and vaccines made thereo f
ATE188708T1 (de) Antikörperderivate
EP0669836A1 (de) Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma.
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0313378A3 (de) Methoden und Zusammensetzungen für vorübergehende Elimination von humoralen immunen Antikörpern
EP0584715A3 (de) Gewinnung und Kultivierung transformierter Zellen und Herstellung gegen sie gerichteter Antikörper.
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ATE256148T1 (de) Menschliche monoklonale antikörper gegen das hepatitis b oberflächenantigen
DK341679A (da) Vaccine mod streptokokker og fremgangsmaade til fremstilling deraf
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
ATE125870T1 (de) Hiv-spezifische monoklonale antikörper und hybridome zu ihrer herstellung.
ATE105938T1 (de) Monoklonale antikörper gegen spezifische antigene regionen des humanen immundefizienzvirus und methoden zur verwendung.
RU99116029A (ru) Применение mycobacterium vaccae для регуляции по типу отрицательной обратной связи th2-активности иммунной системы
NO951768L (no) Fremgangsmåte for fremstilling av monoklonale menneske-antistoffer som er aktive mot Hepatit B-overflateantigen
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
ATE138200T1 (de) Das von mca-28a32 erkannte antigen
ATE21484T1 (de) An menschliche fibroblastenzellen adaptierte hepatitis-a-viren.
ATE137674T1 (de) Von mca 16-88 erkanntes antigen
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza
UA32341A (uk) Спосіб одержання антиадгезивної та антитоксичної сироватки проти сальмонельозів та ешерихіозів тварин
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties